These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 29064182)

  • 41. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
    Albert NM
    Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management of patients with atrial fibrillation and chronic kidney disease in light of the latest guidelines.
    Młodawska E; Tomaszuk-Kazberuk A; Łopatowska P; Musiał WJ; Małyszko J
    Pol Arch Med Wewn; 2016 May; 126(5):353-62. PubMed ID: 27243343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk.
    Bhatia HS; Hsu JC; Kim RJ
    Clin Cardiol; 2018 Oct; 41(10):1395-1402. PubMed ID: 30259531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [NOACs and Chronic kidney disease].
    Di Lullo L; Barbera V; Bellasi A; Cozzolino M; Russo D; Otranto G; Santoboni F; Ronco C
    G Ital Nefrol; 2017 Mar; 34(Suppl 69):188-204. PubMed ID: 28682039
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
    Deedwania PC; Huang GW
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):265-75. PubMed ID: 21740079
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF.
    Chan KE; Giugliano RP; Patel MR; Abramson S; Jardine M; Zhao S; Perkovic V; Maddux FW; Piccini JP
    J Am Coll Cardiol; 2016 Jun; 67(24):2888-99. PubMed ID: 27311528
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease.
    Yang F; Hellyer JA; Than C; Ullal AJ; Kaiser DW; Heidenreich PA; Hoang DD; Winkelmayer WC; Schmitt S; Frayne SM; Phibbs CS; Turakhia MP
    Heart; 2017 Jun; 103(11):818-826. PubMed ID: 27852694
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
    Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH
    Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Flaker G; Lopes RD; Hylek E; Wojdyla DM; Thomas L; Al-Khatib SM; Sullivan RM; Hohnloser SH; Garcia D; Hanna M; Amerena J; Harjola VP; Dorian P; Avezum A; Keltai M; Wallentin L; Granger CB;
    J Am Coll Cardiol; 2014 Oct; 64(15):1541-50. PubMed ID: 25301455
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent evidence for direct oral anticoagulants in chronic kidney disease.
    Ha JT; Badve SV; Jun M
    Curr Opin Nephrol Hypertens; 2019 May; 28(3):251-261. PubMed ID: 30789840
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.
    Molteni M; Bo M; Di Minno G; Di Pasquale G; Genovesi S; Toni D; Verdecchia P
    Intern Emerg Med; 2017 Jun; 12(4):425-435. PubMed ID: 28439778
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial.
    Hijazi Z; Hohnloser SH; Andersson U; Alexander JH; Hanna M; Keltai M; Parkhomenko A; López-Sendón JL; Lopes RD; Siegbahn A; Granger CB; Wallentin L
    JAMA Cardiol; 2016 Jul; 1(4):451-60. PubMed ID: 27438322
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
    Van Der Meersch H; De Bacquer D; De Vriese AS
    Am Heart J; 2017 Feb; 184():37-46. PubMed ID: 27892885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
    Bohula EA; Giugliano RP; Ruff CT; Kuder JF; Murphy SA; Antman EM; Braunwald E
    Circulation; 2016 Jul; 134(1):24-36. PubMed ID: 27358434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atrial fibrillation and chronic kidney disease conundrum: an update.
    Tapoi L; Ureche C; Sascau R; Badarau S; Covic A
    J Nephrol; 2019 Dec; 32(6):909-917. PubMed ID: 31321745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.